Table III.
Diagnostic performance of candidate genes.
| Gene | BC pos./total | BBD pos./total | Sensitivity (%) | Specificity (%) | AUC | 95% CI | P-value |
|---|---|---|---|---|---|---|---|
| BRCA1 | 17/70 | 0/20 | 24.3 | 100.0 | 0.621 | 0.497–0.745 | 0.099 |
| GSTP1 | 22/70 | 0/20 | 31.4 | 100.0 | 0.657 | 0.540–0.775 | 0.033 |
| P16INK4A | 28/70 | 4/20 | 40.0 | 80.0 | 0.600 | 0.465–0.735 | 0.174 |
| MGMT | 19/70 | 5/20 | 27.1 | 75.0 | 0.511 | 0.367–0.654 | 0.884 |
| PTEN | 34/70 | 8/20 | 48.6 | 60.0 | 0.543 | 0.400–0.686 | 0.560 |
| RARβ2 | 39/70 | 8/20 | 55.7 | 60.0 | 0.579 | 0.437–0.720 | 0.286 |
| CCND2 | 47/70 | 9/20 | 67.1 | 55.0 | 0.611 | 0.468–0.754 | 0.133 |
BC, breast cancer; BBD, benign breast disease; AUC, area under the curve; CI, confidence interval; pos., positive; BRCA1, breast cancer 1, early onset; DNA repair associated; GSTP1, glutathione S-transferase pi 1; P16INK4A, cyclin dependent kinase inhibitor 2A; MGMT, O-6-methylguanine-DNA methyltransferase; PTEN, phosphatase and tensin homolog; RARβ2, retinoic acid receptor beta 2; CCND2, cyclin D2.